Edaravone for the treatment of amyotrophic lateral sclerosis

References

• Mehta P, Antao V, Kaye W, et al. Prevalence of amyotrophic lateral sclerosis — United States, 2010–2011. Surveillance Summaries. 2014;63(SS07):1–14.
   Google Scholar
• Orphanet report series – prevalence of rare diseases: bibliographic data - January 2018 – Number 1
   Google Scholar
• Couratier P, Corcia P, Lautrette G, et al. Epidemiology of amyotrophic lateral sclerosis: a review of literature. Revue Neurol. 2016;172:37–45.
   PubMed Web of Science ®Google Scholar
• Practical guideline for ALS 2013 in Japan.
   Google Scholar
• Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:191–206.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127–1138.
   PubMed Web of Science ®Google Scholar
• Beal MF, Ferrante RJ, Browne SE, et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997;42:644–654.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Yamazaki K, et al. Remarkable increase in cerebrospinal fluid 3-nitotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999;46:129–131.
   PubMed Web of Science ®Google Scholar
• Kanouchi T, Ohkubo T, Yokota T. Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like properties? J Neurol Neurosurg Psychiatry. 2012;83:739–745.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Tanaka M, Yuki S, et al. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr. 2017;11:1–19.
   Google Scholar
• Thonhoff JR, Simpson EP, Appel SA. Neuroinflammation mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;35:635–639.
   Google Scholar
• Komatsu T, Nakai H, Masaki K, et al. Pharmacokinetic studies of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186) in rats (1): blood and plasma levels, distribution, metabolism and excretion after a single intravenous administration. Xenobio Metabol Dispos (Japanese). 1996;11:463–480.
   Google Scholar
• Yamamoto Y, Kuwahara T, Watanabe K, et al. Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Rep. 1996;2:333–338.
   PubMed Web of Science ®Google Scholar
• Takamatsu Y, Watanabe T. Studies on the concentrations of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186) in dog plasma and cerebral spinal fluid. Pharmacol Ther (Japanese). 1997;25(Supp l7):s1793–s1797.
   Google Scholar
• Watanabe T, Yuki S, Saito K, et al. Pharmacological studies of MCI-186, a new drug for acute stroke. Pharmacol Ther (Japanese). 1997;25(Suppl 7):s1691–s1698.
   Google Scholar
• Knorr L. Einwirkung von acetessigester auf phenylhydrazin. Ber Deut Chem Ges. 1883;16:2597–2599.
   Google Scholar
• Watanabe K, Watanabe K, Hayase T. Radical scavenging mechanism of MCI-186. Jpn Pharmacol Ther. 1997;25(Suppl 7):s1699–s1707.
   Google Scholar
• Yoshino H, Kimura A. Clinical trial for amyotrophic lateral sclerosis with free radical scavenger, edaravone. Neurol Ther (Japanese). 2003;20:557–564.
   Google Scholar
• Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7:247–251.
   Web of Science ®Google Scholar
• Nakamura N, Kinoshita S, Kawaguchi A, et al. Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations. Amyotrph Lateral Scler Frontotemporal Degener. 2017;18(Suppl 1):80–87.
   PubMedGoogle Scholar
• Otomo E, Tohgi H, Kogure K, et al. Clinical efficacy of a free radical scavenger, MCI-186, on acute cerebral infarction: early phase II clinical trial. Ther Res. 1998;19:1311–1332.
   Google Scholar
• The Edaravone Acute Brain Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction: randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15:222–229.
   PubMed Web of Science ®Google Scholar
• Hishida A. Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone. Clin Exp Nephrol. 2009;13:118–122.
   PubMed Web of Science ®Google Scholar
• Yoshino H. Safety and efficacy of edaravone, a free radical scavenger, in the treatment of ALS: randomized, double-blind, placebo-controlled study. Neurol Ther (Japanese). 2016;33:46–52.
   Google Scholar
• Koji A, Itoyama Y, Sobue G, et al. Confirmative double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotrph Lateral Scler Frontotemporal Degener. 2014;15:610–617.
   PubMed Web of Science ®Google Scholar
• The Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase Ⅲ clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrph Lateral Scler Frontotemporal Degener. 2017;18(Supp l1):11–19.
   PubMedGoogle Scholar
• The Writing Group on behalf of the Edaravone (MCI-186) ALS 17 Study Group. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrph Lateral Scler Frontotemporal Degener. 2017;18(Suppl e1):20–31.
   PubMedGoogle Scholar
• Fumihiro T, Takei K, Tsuda K, et al. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Amyotrph Lateral Scler Frontotemporal Degener. 2017;18(Suppl e1):32–39.
   Google Scholar
• The Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–512.
   PubMed Web of Science ®Google Scholar
• Hirai M, Ishizaki K, Matsuda H, et al. Surveillance of using novel free radical scavenger, edaravone to investigate survival effect for ALS patients in Japan (SUNRISE Japan): a study design. J Neurol Sci. 2017;381:207.
   Web of Science ®Google Scholar
• Kaufmann P, Levy G, Thompson JLP, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64:38–43.
   PubMed Web of Science ®Google Scholar
• Leigh PN, Swash M, Iwasaki Y, et al. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:84–98.
   PubMed Web of Science ®Google Scholar
• Okada M, Yamashita S, Ueyama H, et al. Long-term effect of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurol Sci. 2018;11:11–14.
   Google Scholar
• Yoshino H. Long term efficacy of edaravone. 29th International Symposium on ALS/MND. Glasgow, Scotland, UK. December 2018.
   Google Scholar
• The Writing Group on behalf of the Edaravone (MCI-186) ALS 18 Study Group. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation). Amyotrph Lateral Scler Frontotemporal Degener. 2017;18(Suppl e1):40–48.
   PubMedGoogle Scholar
• Takei K, Takahashi F, Liu S, et al. Post-hoc analysis of randomized, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrph Lateral Scler Frontotemporal Degener. 2017;18(Supple 1):49–54.
   PubMedGoogle Scholar
• Kalin A, Medina-Paraiso E, Ishixaki K, et al. A Safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in the three randomized, placebo-controlled studies. Amyotrph Lateral Scler Frontotemporal Degener. 2017;18(Supple 1):71–79.
   PubMedGoogle Scholar
• Koji T, Omura T, Nakamura Y et al. Radicava (edaravone) for amyotrophic lateral sclerosis: new formulation and its development plan. 29th International Symposium on ALS/MND. Glasgow, Scotland, UK. December 2018.
   Google Scholar